The Steep Decline

However, the euphoria surrounding 23andMe's public debut was short-lived. In the years since going public, the company has experienced a dramatic reversal of fortunes. Several factors have contributed to this decline:

1. Market Saturation: The initial excitement around consumer genetic testing has waned. Many potential customers who were interested in ancestry or trait information have already purchased kits, leading to a slowdown in new sales.